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Rare disease
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by antibodies directed against phospholipids on plasma membranes. Through unclear mechanisms, APS confers hypercoagulability. APS may cause
recurrent thromboses in the arterial and venous vasculature. We report a case of primary APS resulting in cerebral venous thrombosis and ST-elevation myocardial infarction (STEMI) for which only antiphosphatidylserine (aPS) IgM antibody was positive after extensive investigation.
A 48-year-old male was admitted after a witnessed generalized seizure with subsequent confusion. Imaging
demonstrated thrombosis of multiple central nervous system (CNS) sinuses, including the superior sagittal sinus and bilateral transverse sinuses. The patient was heparinized with aggressive hydration, which proved inadequate, prompting endovascular thrombectomy. Three months later, despite anticoagulation therapy, the
patient developed a STEMI when International Normalized Ratio (INR) was 1.8. Echocardiogram (ECHO) and
PAN CT scan were normal. Initial coagulation studies demonstrated normal anticardiolipin antibody, prothrombin time, partial thromboplastin time, and platelet count. Outpatient coagulation studies revealed normal antithrombin III, protein C/S, hemoglobin electrophoresis, homocysteine, anti-b2 glycoprotein 1 antibodies, and
D-Dimer. Factor V Leiden, JAK 2 mutation, prothrombin gene mutation, and tests for paroxysmal nocturnal hemoglobinuria (PNH) were negative. A positive phosphatidylserine IgM was detected. The patient was continued on warfarin (10 mg daily) with a target INR of 3.0–3.5 and clopidogrel (75 mg daily).
Despite extensive investigation, this patient only showed evidence of elevated aPS IgM antibodies, likely contributing to his CNS venous sinus thromboses and STEMI. It is important to screen for antiphosphatidylserine
antibodies in cases of unprovoked thrombosis when standard thrombophilia analysis is unrevealing. This will
assist in identifying pathogenicity and help prevent recurrence of subsequent thromboses.
Antiphospholipid Syndrome • Intracranial Thrombosis • Phosphatidylserines • Thrombophilia
https://www.amjcaserep.com/abstract/index/idArt/909698
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Background
Antiphospholipid syndrome (APS) is an acquired autoimmune disorder that results in a hypercoagulable state characterized by recurrent venous and/or arterial thrombosis [1].
Antiphospholipid antibodies are directed against proteins
that bind to anionic phospholipids on plasma membranes [2].
APS can be characterized as a primary or secondary disorder
and is more frequently seen in women, particularly those who
have pregnancy-related complications such as miscarriage,
stillbirth, or preterm delivery [3]. APS may contribute to an
increased frequency of stroke or myocardial infarction (MI),
especially in younger individuals [3]. Laboratory classification
of APS requires the presence of at least one of the following:
lupus anticoagulant, moderate to high levels of anticardiolipin antibodies (aCL), and/or moderate to high levels of anti-b2
glycoprotein 1 antibodies (Anti-b2GP1) [3]. Anticardiolipin antibody testing should include cardiolipin and b2GP1, as well
as the individual isotypes IgG, IgM, and IgA. While various risk
factors can contribute to the formation of a venous thromboembolism (VTE), it is important to keep APS in the differential
diagnosis, especially when thrombosis is unprovoked. Here,
we report an uncommon case of primary APS resulting in cerebral venous thrombosis and STEMI, for which only aPS IgM
antibody was positive after an extensive workup.

Figure 1. Axial FLAIR MRI reveals hyperintensity consistent with
left temporal lobe edema (arrow) and small linear
hemorrhages.

Case Report
A 48-year-old white male was taken to the emergency room
after his family witnessed a generalized seizure and noted subsequent prolonged confusion and agitation in February 2017.
Glasgow coma scale (GCS) was 13 upon admission. Computed
tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance venography (MRV) demonstrated thrombosis
of multiple CNS sinuses. MRI demonstrated left temporal lobe
edema and small linear hemorrhages (Figure 1). MRV and conventional angiography demonstrated cerebral venous thrombosis of multiple CNS sinuses including a vertebral artery occlusion of unknown chronicity and bilateral transverse sinus
thrombosis, as well as straight sinus and superior sagittal sinus thrombosis (Figure 2). The patient was placed on levetiracetam, systemic heparin, and aggressive hydration without
difficulty, but suffered progressive clinical worsening requiring endovascular mechanical venous suction thrombectomy,
resulting in good angiography effect (Figure 3). The initial coagulation workup was completed and demonstrated normal
aCL, prothrombin time (PT), and activated partial thromboplastin time (APTT).

Figure 2. Contrast-enhanced coronal MRV demonstrating
extensive superior sagittal sinus thrombosis (horizontal
arrow) affecting the right transverse sinus (vertical
arrow).

The patient denied any past medical history or surgical history
prior to the thrombotic event. He denied a history of tobacco
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At his outpatient hematology follow-up, physical examination
revealed normal vital signs. He was obese with a body mass
index (BMI) of 31.4kg/m2.
The neck examination was normal, showing supple without
lymphadenopathy. The skin examination was normal, with
no heliotrope rash, malar rash, acrocyanosis, or livedo reticularis. Bilateral heart and lung examination results were normal.
No carotid bruits were noted. The abdomen was soft, nontender, and non-distended with no hepatosplenomegaly.
The neurological examination was normal. Distal pulses were
palpable and lower extremities were without edema or cyanosis.
A bilateral lower-extremity venous Doppler was negative.
A PAN CT scan was done to rule out underlying malignancy
and was negative.

Figure 3. Coronal MRV contrast injection revealing improved
drainage through superior sagittal sinus (horizontal
arrow) and transverse sinus (vertical arrow) after
venous sinus aspiration thrombectomy.

and illicit drug use. He did report drinking two 12-ounce cans
of beer per month.
His family history was unremarkable for familial thrombotic
tendency or autoimmune disease. His maternal uncle reportedly had polycythemia vera, his paternal grandfather had prostate cancer, and his maternal grandmother had bone cancer.
The patient was discharged 6 days after admission on warfarin, enoxaparin, and levetiracetam with an appointment to
follow up with hematology to begin an outpatient thrombophilia workup.
While undergoing an outpatient workup, in May 2017, just
3 months after his initial presentation, he developed burning retrosternal chest pain with radiation to the left arm.
An electrocardiogram (EKG) showed sinus rhythm with inverted T waves inferiorly, which proved to be a ST-elevation
myocardial infarction (STEMI); simultaneously, International
Normalized Ratio (INR) revealed a level of 1.8. Intravenous
heparin was commenced. Echo showed normal left ventricular systolic function with middle inferior hypokinesis. Coronary
angiography indicated evidence of obstructive coronary artery disease with 50% stenosis in the left circumflex artery,
30% stenosis in the distal left anterior descending artery, and
40% stenosis in the proximal left anterior descending artery.
The patient was discharged 5 days after admission on enoxaparin 120 mg subcutaneous injection twice daily, clopidogrel
75 mg daily, atorvastatin 40 mg daily, and lisinopril 10 mg daily.
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Laboratory studies included a general hematology analysis,
which was within normal limits with the exception of a low
platelet count (120×103/uL), which recovered to 159×103/uL
within 2 months. Studies showed a white blood cell count of
6.0×103/uL and a normal hemoglobin of 14.0 g/dL.
His general chemistry results were normal.
Based on past thrombotic and embolic events, despite anticoagulation therapy, a full hypercoagulability workup was completed, including protein C, protein S, antithrombin III, factor
V Leiden, D-dimer, fibrinogen, flow cytometry for paroxysmal
nocturnal hemoglobinuria (PNH), homocysteine, hemoglobin
electrophoresis, factor VIII, factor X, complement, plasminogen
activator inhibitor (PAI) screen, JAK2 mutation detection, prothrombin gene mutation screen, antiphospholipid antibodies,
and beta-2 glycoprotein 1 antibodies (Table 1). General coagulation tests prior to warfarin initiation showed normal prothrombin time (PT: 10.5 s), International Normalized Ratio (INR)
1.0, normal activated partial thromboplastin time (APTT: 28.5 s),
and negative D-dimer of <0.20 mg/L FEU. Protein C, protein S,
antithrombin III, fibrinogen, homocysteine, complement levels, and hemoglobin electrophoresis were normal. Factor VIII
activity was just slightly above the normal range, while factor
X was low. He lacked factor V Leiden and prothrombin gene
mutation. JAK2 and PAI genotype were normal. Flow cytometry was negative for PNH. Cardiolipin antibodies were normal
(IgG: <9; IgM: 13; IgA: <9). Beta-2 glycoprotein 1 antibodies
were normal (IgG: <9; IgM: <9; IgA: <9). Of note, his phosphatidylserine antibodies (IgM) were significantly positive, with a
value of 45. Phosphatidylserine antibodies IgG and IgA were
normal (IgG: 1; IgA: 1).
The patient was continued on clopidogrel (75 mg daily) and
transitioned from enoxaparin (120 mg, twice per day) to warfarin (10 mg daily) with a target INR of 3.0–3.5.
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Table 1. Hypercoagulability profile.
Result
Prothrombin time (PT)

Value/result

Units

Range

10.5

Seconds

9.1–12.0

International normalized ratio (INR)

1.0

Partial thromboplastin time (APTT)

28.5

Seconds

24.0–33.0

Protein C – functional

117

%

73–180

Protein S, total

120

%

60–150

94

%

Antithrombin III activity
Factor V Leiden mutation
D-Dimer
Fibrinogen
Flow cytometry PNH*
Homocysteine
Hemoglobin solubility**

0.8–1.2

Negative

75–135
Negative

<0.20

mg/L FEU

0.00–0.49

291

mg/dL

193-507

No evidence of PNH
11.7

No evidence of PNH
umol/L

Negative

Factor VIII activity

168

Factor X activity
Complement, total

0.0–15.0
Negative

%

56–163

15

%

76–183

56

U/ml

42–60

PAI-1 activity

5G/5G***

JAK2 mutation inhibitor

Negative

Negative

Prothrombin gene mutation

Negative

Negative

Anticardiolipin Ab, IgG

<9

U/ml

0–15

Anticardiolipin Ab, IgM

13

U/ml

0–12

Anticardiolipin Ab, IgA

<9

U/ml

0–11

Beta-2 glycoprotein I Ab, IgG

<9

GPI IgG units

0–20

Beta-2 glycoprotein I Ab, IgM

<9

GPI IgM units

0–32

Beta-2 glycoprotein I Ab, IgA

<9

GPI IgA units

0–25

Antiphosphatidylserine IgG

1

GPS IgG

0–11

Antiphosphatidylserine IgM

45

MPS IgM

0–25

Antiphosphatidylserine IgA

1

APS IgA

0–20

* Peripheral blood specimen; ** normal adult hemoglobin present; *** homozygous for 5G insertion allele which is associated with the
lowest PAI-1 activity.

Discussion
Phosphatidylserine is a negatively charged phospholipid that
is a component of the cellular membrane. This phospholipid acts as a procoagulant when activated by collagen, thrombin, or antibodies, resulting in a hypercoagulable state [2].
While phosphatidylserine is not the most common antiphospholipid antibody (aPL), it serves as a significant antigenic target in APS [4]. Antiphospholipid syndrome is characterized by
a prothrombotic state that can occur in both venous and arterial vasculature [5].
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The most common aPLs include lupus anticoagulant, aCL, and
anti-b2GP1 [4]. These aPLs react with phospholipids and proteins
on the venous and arterial vasculature, ultimately resulting in
thrombosis [4]. b2GP1 is the most common of these antibodies
and is found in the vast majority of seropositive APS patients [4].
The most common sites of thrombosis consist of cerebral arterial vasculature and the lower-extremity venous system [5].
The clinical presentation of APS most commonly includes pulmonary embolism (PE), deep venous thrombosis (DVT), and/or
thrombosis in the arterial system [3]. The initial presentation may or may not be associated with dermatologic manifestations such as livedo reticularis and a heliotrope rash [3].
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In women of child bearing age, obstetric complications such
as miscarriage and stillbirth may be the initial presentation of
APS [3]. Thrombosis is the most common initial presentation
and is typically diagnosed by CT, MRI, MRV, or Doppler ultrasound to confirm a thrombotic event in the brain, chest, abdomen, or deep veins of the lower extremities.
The differential diagnosis when encountering a patient with
thrombophilia can be extensive. Malignancy may initially present with thrombotic tendencies and should be ruled out with
imaging. Homocystinemia, antithrombin III deficiency, protein
C or S deficiency, factor V Leiden mutation, and prothrombin
gene mutation should be considered in patients who exhibit thrombophilia [6]. Atherosclerotic vascular disease should
also be ruled out in patients presenting with prothrombotic
tendencies. The workup for a hypercoagulable state should
investigate both inherited and acquired conditions that may
contribute to a procoagulant state [6].
The diagnosis of APS is primarily based on the detection of antiphospholipid antibodies in a patient’s serum and evidence of
thrombosis [7]. Triple positivity of lupus anticoagulant, anticardiolipin antibodies, and beta-2 glycoprotein 1 antibodies create
the highest risk of thromboembolic events [7]. Deficiencies in
protein C, protein S, and antithrombin should be explored, as
well as mutations, including factor V Leiden, prothrombin, and
plasminogen inhibitor genes [6]. Antibodies directed against
phosphatidylserine should also be considered when initial APS
studies are negative [7]. Recent studies have demonstrated a
significant association between aPS and APS, and seronegative APS patients have been found to be positive for aPS [8,9].
The mainstay of treatment for thrombotic events associated
with APS primarily consists of anticoagulation [10]. In certain
circumstances aspirin and heparin may be used, but warfarin
is the most commonly prescribed anticoagulant for treatment
of APS [10]. Recent research emphasizes the importance of indefinite anticoagulation for patients who have had a thrombotic event, due to the high recurrence risk [10].

The patient discussed in this case report is a prime example
of a seronegative APS patient who tested positive only for aPS
after an extensive thrombophilia workup. This patient did not
have any significant risk factors that would have contributed to his thrombophilia. He denied recent hospitalization, immobilization, and smoking, showed no evidence of malignancy, and had no personal or family history of clotting disorders.
The patient’s mild obesity and positive phosphatidylserine IgM
were the only apparent contributing factors. Of note, a recent
case report described multiple etiologies in a lower-extremity DVT, including significantly positive phosphatidylserine IgG
antibodies, which demonstrates the importance of this as a
risk factor for thrombosis [11]. At 1-year follow-up, the patient
had not developed any autoimmune or collagen vascular diseases. This study suggests further investigation into the possibility of phosphatidylserine antibodies in individuals with
clinical symptoms related to thrombosis with an exhaustive,
unrevealing clinical workup.

Conclusions
It is important to consider other uncommon causes for thrombophilia, such as APS. Laboratory testing should include the common disorders that result in thrombophilia, but if results are unrevealing, further workup is necessary. Antiphosphatidylserine
antibodies should be considered if there is a high index of suspicion for a hypercoagulable state in patients who have a pannegative standard thrombophilia workup.
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